Related Experiment Video
Updated: Jun 23, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Proof of concept studies for tissue-protective agents in multiple sclerosis
L R Mehta1, S R Schwid, D L Arnold
1University of Rochester Department of Neurology, Rochester, NY, USA. lahar_mehta@urmc.rochester.edu
Background:
There is considerable interest in tissue-protective treatments for multiple sclerosis (MS).
Methods And Objectives:
We convened a group of MS clinical trialists and related researchers to discuss designs for proof of concept studies utilizing currently available data and assessment methods.
Results:
Our favored design was a randomized, double-blind, parallel-group study of active treatment versus placebo focusing on changes in brain volume from a post-baseline scan (3-6 months after starting treatment) to the final visit 1 year later. Study designs aimed at reducing residual deficits following acute exacerbations are less straightforward, depending greatly on the anticipated rapidity of treatment effect onset.
Conclusions:
The next step would be to perform one or more studies of potential tissue-protective agents with these designs in mind, creating the longitudinal data necessary to refine endpoint selection, eligibility criteria, and sample size estimates for future trials.
Insights
Researchers propose a new study design for multiple sclerosis (MS) tissue-protective treatments. The favored design is a randomized, double-blind trial focusing on brain volume changes over one year.
Area of Science:
- Neuroscience
- Clinical Trials
- Immunology
Background:
- Multiple sclerosis (MS) research shows significant interest in treatments that protect tissue.
- Developing effective disease-modifying therapies for MS remains a critical clinical challenge.
Purpose of the Study:
- To discuss and propose optimal study designs for proof-of-concept trials evaluating tissue-protective agents in multiple sclerosis.
- To leverage existing data and assessment methodologies for designing future clinical investigations.
Main Methods:
- Convened a group of multiple sclerosis (MS) clinical trialists and researchers.
- Discussed and favored a specific study design for proof-of-concept investigations.
- Considered various assessment methods and data available for trial design.
Main Results:
- The favored design is a randomized, double-blind, parallel-group study comparing active treatment to placebo.
- The primary endpoint focuses on changes in brain volume measured from a 3-6 month post-baseline scan to a 1-year follow-up.
- Designing studies to reduce deficits after acute exacerbations is complex and depends on treatment onset speed.
Conclusions:
- The proposed designs provide a framework for future clinical trials of tissue-protective agents in MS.
- Conducting these studies will generate essential longitudinal data.
- This data will refine endpoint selection, eligibility criteria, and sample size estimations for subsequent MS trials.
